Fig 4. Detailed clinical course of a patient with portal thrombosis after lusutrombopag treatment.

(A) Changes in platelet counts during and after lusutrombopag therapy. This patient had a prior history of portal thrombosis. Initially, 3 mg of lusutrombopag was administered from day 1 to day 5. Since the platelet count increased to 76,000/μL on day 5, the administration of lusutrombopag was discontinued. After RFA, portal thrombosis was detected and antithrombotic therapy with antithrombin III (for 3 days) plus danaparoid sodium (for 14 days) was given which resulted in the complete resolution of portal thrombosis. (B) Course of image findings. The arrowheads show HCC recurrence in the third segment of the liver. Dynamic CT imaging on day 12 shows the areas of ablation by RFA. Portal thrombosis occurred on CT on day 12 of lusutrombopag therapy requiring antithrombotic therapy. Complete resolution of thrombosis on day 90. HCC: hepatocellular carcinoma, RFA: percutaneous radiofrequency ablation.